Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...
HealthDay on MSN7d
15.4% of 0- to 35-Month-Olds Receive Invalid Vaccine Dose
Overall, 15.4% of children aged 0 to 35 months receive an invalid vaccine dose, receiving a vaccine earlier or later than recommended.
centerforbiosimilars3d
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
Nasdaq4d
Larimar Therapeutics Begins Dosing Adolescents in Pediatric Study for Friedreich's Ataxia
Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia.
Morningstar5d
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
“Dosing adolescents is the first step in evaluating the safety and PK of nomlabofusp in pediatric patients with FA. We continue to enroll adolescents in our first cohort. This cohort will be ...
Finanznachrichten4d
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
"Dosing adolescents is the first step in evaluating the safety and PK of nomlabofusp in pediatric patients with FA. We continue to enroll adolescents in our first cohort. This cohort will be ...